| scholarly article | Q13442814 |
| P50 | author | Yehuda Patt | Q8051301 |
| Jean-Nicolas Vauthey | Q43369878 | ||
| Ajay K Nooka | Q88643491 | ||
| Steven A Curley | Q88849410 | ||
| Richard D Lozano | Q114423654 | ||
| Chusilp Charnsangavej | Q114446432 | ||
| Manal Hassan | Q124061116 | ||
| Lee M Ellis | Q124061137 | ||
| P2093 | author name string | Robert A Wolff | |
| Thomas D Brown | |||
| Alvaro Aguayo | |||
| Isac I Schnirer | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | capecitabine | Q420207 |
| hepatocellular carcinoma | Q1148337 | ||
| gallbladder carcinoma | Q18556564 | ||
| cholangiocarcinoma | Q124292 | ||
| P304 | page(s) | 578-586 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma | |
| P478 | volume | 101 |
| Q28392783 | 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma |
| Q28394414 | 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma |
| Q64272871 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q91599660 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q33368148 | A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. |
| Q43197898 | A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma |
| Q87691280 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma |
| Q33378789 | A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma |
| Q33399656 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients |
| Q37977363 | Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction |
| Q39025911 | Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States |
| Q38082318 | Advances in the management of biliary tract cancers |
| Q28468615 | Antitumor effect of forbesione isolated from Garcinia hanburyi on cholangiocarcinoma in vitro and in vivo |
| Q58701446 | Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma |
| Q30479629 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma |
| Q47969105 | Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer |
| Q43589273 | Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study |
| Q36614800 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial |
| Q33428348 | Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma |
| Q33977171 | Chemotherapy and targeted therapy for gall bladder cancer |
| Q36572534 | Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? |
| Q37983498 | Chemotherapy for the biliary tract cancers: moving toward improved survival time |
| Q33593207 | Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function |
| Q36962011 | Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives |
| Q35791442 | Cholangiocarcinoma: prognostic factors after surgical resection in China. |
| Q35298023 | Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review |
| Q38410816 | Current management of hepatocellular carcinoma: an Eastern perspective |
| Q36927562 | DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. |
| Q34410337 | Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines |
| Q42746639 | Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine |
| Q33388581 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma |
| Q33747394 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma |
| Q37050501 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments |
| Q37293105 | Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience |
| Q36989921 | Emerging drugs for biliary cancer |
| Q35059751 | Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma. |
| Q26784174 | Gallbladder Cancer in the 21st Century |
| Q37255709 | Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction |
| Q34588361 | Guidelines for chemotherapy of biliary tract and ampullary carcinomas |
| Q42053469 | Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy |
| Q46933047 | Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide |
| Q39205529 | Is Para‐aortic Lymph Node Metastasis a Contraindication for Radical Resection in Biliary Carcinoma? |
| Q38110989 | Metaanalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangiocarcinoma |
| Q34487968 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells |
| Q48105164 | Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation |
| Q41937355 | Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases |
| Q37637994 | Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study |
| Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
| Q33376718 | Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. |
| Q38130469 | Multidisciplinary approaches to intrahepatic cholangiocarcinoma |
| Q36962430 | Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein |
| Q33635033 | Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. |
| Q33372640 | Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer |
| Q38030862 | Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics |
| Q83292338 | Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma |
| Q33443438 | Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. |
| Q33378906 | Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis |
| Q39970084 | Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy |
| Q64913937 | Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. |
| Q37738084 | Protein Regulator of Cytokinesis PRC1 Confers Chemoresistance and Predicts an Unfavorable Postoperative Survival of Hepatocellular Carcinoma Patients. |
| Q25257445 | Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study |
| Q50173075 | Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma |
| Q47869247 | Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma |
| Q37449054 | Role of liver transplantation in the treatment of cholangiocarcinoma |
| Q35947011 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
| Q90412923 | Safety and Efficacy of Low-Dose Single-Agent Capecitabine in Inoperable Gallbladder Cancer with Jaundice Post-Single-System Single-Catheter External Biliary Drainage: a Pilot Study from a Highly Endemic Area |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q44921787 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma |
| Q35173757 | Surgical procedure and long-term survival of hilar cholangiocarcinoma |
| Q37135733 | Systemic Therapy in Hepatocellular Carcinoma |
| Q95806910 | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| Q37734197 | Systemic therapy for advanced hepatocellular carcinoma: past, present, and future |
| Q33854034 | Systemic treatment of hepatocellular carcinoma: Past, present and future |
| Q64886353 | Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. |
| Q35207561 | Targeted therapy in hepatocellular carcinoma |
| Q33916021 | Targeting cancers in the gastrointestinal tract: role of capecitabine |
| Q28476545 | Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma |
| Q33388402 | The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma |
| Q45082632 | The evolving landscape of therapeutic drug development for hepatocellular carcinoma |
| Q40428440 | Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration |
Search more.